Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynthomer Regulatory News (SYNT)

Share Price Information for Synthomer (SYNT)

Share Price is delayed by 15 minutes
Get Live Data
105.00    1.80 (1.74%)
Bid:
104.40
Ask:
105.20
Spread: 0.80 (0.766%)
Market Cap: £172.14m
SYNT Live PriceLast checked at - London Stock Exchange

Intraday Synthomer Share Chart

Update

29 Dec 2008 07:00

RNS Number : 7991K
Yule Catto & Co PLC
29 December 2008
 



29 December 2008

Yule Catto & Co plc

Update

Yule Catto & Co plc ("the Group") is pleased to announce that it has signed a new three year £30 million revolving loan facility with its principal banks, HSBC and Barclays. This loan replaces its existing revolving bank loan facility maturing in November 2009.

During the course of this re-financing, the Board has been carefully considering the capital structure of the Group.  Whilst much progress has been made on the deleveraging of the balance sheet, with £55 million of gross proceeds received from the sale of three of our five Impact Chemicals businesses, the balance sheet remains a core focus of the Board and it aims to reduce outstanding net debt to below £100 million over the next twelve to twenty four months. The Board believes this is consistent with the Group's objectives, including its financial commitments to the Group's UK pension fund.

Accordingly, and in light of the current financial environment and economic uncertainty, the Board has additionally decided to suspend the payment of dividends until such time as net debt is nearer to its overall target and at which time the business environment and financial market conditions may well have improved. The Board anticipates reverting to the payment of a dividend within two years.

At the time the Group recommences the payment of a dividend, the Board anticipates rebasing it to a level determined by comparison with its peer group and which will allow an appropriate free cash flow to suit the Group's circumstances.

The Board is also pleased to confirm that for 2008 the Group still expects to deliver underlying earnings before tax modestly ahead of last year, despite the current difficult economic conditions particularly in the UK and Continental Europe.

The Board believes it is too early at this time, given the prevailing economic uncertainty, to offer any firm guidance on the outturn for 2009.  The Group's Impact Chemicals and Pharma Chemicals businesses should benefit next year from recent restructuring.  Within our Polymer Chemicals business we anticipate the performance of our Asian and Middle East businesses to be more robust than that of our European businesses, due to local market conditions and a more resilient demand profile from our targeted markets. In addition, the current relative weakness of Sterling against the Dollar, Euro and Malaysian Ringgit, should it continue, will assist the reported Sterling earnings for a number of our businesses.

The Group continues to look at ways to improve efficiency and minimise costs. We currently have a number of initiatives in hand to do this, both within Europe and the rest of the world. 

These are exceptional times, with a high degree of market uncertainty and a very difficult environment for funding.  Having completed £55 million of divestments and put in place a new revolving loanthe Board believes that, together with internal actions to conserve cash and the suspension of the dividend, Yule Catto is now well placed to weather these conditions.

- Ends -

For further information, please contact:

Yule Catto & Co plc
Adrian Whitfield, Chief Executive
David Blackwood, Group Finance Director
 
01279 442791
Hogarth Partnership 
John Olsen
Andrew Jaques
Ian Payne
020 7357 9477
07770 272082

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCFKQKNNBDDFBB
Date   Source Headline
13th Jul 201210:38 amRNSChange of Auditor
6th Jul 20129:38 amRNSHolding(s) in Company
3rd Jul 20124:35 pmRNSHolding(s) in Company
2nd Jul 201212:46 pmRNSHolding(s) in Company
2nd Jul 201211:11 amRNSDirector/PDMR Shareholding
27th Jun 20127:00 amRNSTrading Statement
12th Jun 201210:30 amRNSDirector/PDMR Shareholding
8th Jun 20122:09 pmRNSDirector/PDMR Shareholding
7th Jun 20124:35 pmRNSDirector/PDMR Shareholding
25th May 201211:00 amRNSDirector Declaration
17th May 201212:22 pmRNSResult of AGM
17th May 201211:00 amRNSDirectorate Change
17th May 20127:00 amRNSInterim Management Statement
14th May 20123:47 pmRNSAnnual Information Update
17th Apr 20129:18 amRNSAnnual Financial Report
3rd Apr 20123:11 pmRNSDirector/PDMR Shareholding
2nd Apr 20127:00 amRNSMarl Site Operations
28th Mar 20125:15 pmRNSHolding(s) in Company
26th Mar 20127:00 amRNSDirector/PDMR Shareholding
23rd Mar 20127:00 amRNSDirectorate Change
19th Mar 20124:10 pmRNSDirector/PDMR Shareholding
16th Mar 20121:48 pmRNSDirector/PDMR Shareholding
16th Mar 20121:46 pmRNSDirector/PDMR Shareholding
16th Mar 20121:09 pmRNSDirector/PDMR Shareholding
14th Mar 20123:52 pmRNSDirector/PDMR Shareholding
14th Mar 20127:00 amRNSFinal Results
11th Jan 20127:00 amRNSTrading Update
9th Jan 201210:24 amRNSDirector/PDMR Shareholding
3rd Jan 20124:51 pmRNSDirector/PDMR Shareholding
1st Dec 20117:00 amRNSDisposal of Pharma Division
25th Nov 20117:00 amRNSDirectorate Change
10th Nov 20117:00 amRNSInterim Management Statement
1st Nov 20113:33 pmRNSHolding(s) in Company
31st Oct 201110:15 amRNSHolding(s) in Company
20th Oct 20112:42 pmRNSHolding(s) in Company
17th Oct 20118:20 amRNSAcquisition
28th Sep 20117:00 amRNSAnalyst and Investor Site Visit
5th Sep 20117:00 amRNSAppointment of Joint Broker
26th Aug 20117:00 amRNSHalf Yearly Report
10th Aug 20118:58 amRNSHolding(s) in Company
4th Aug 20119:02 amRNSBoard appointment
27th Jul 20111:12 pmRNSHolding(s) in Company
29th Jun 20114:46 pmRNSDirector/PDMR Shareholding
29th Jun 20114:44 pmRNSDirector/PDMR Shareholding
29th Jun 20112:17 pmRNSResult of EGM
22nd Jun 20113:59 pmRNSHolding(s) in Company
16th Jun 20114:39 pmRNSHolding(s) in Company
16th Jun 20114:37 pmRNSHolding(s) in Company
13th Jun 201111:14 amRNSNotice of EGM
9th Jun 201110:44 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.